Plain-English translation of NCT07481357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called for people with advanced stomach cancer, gastro-esophageal cancer, or pancreatic cancer. The study will test different doses of this medication given as an intravenous infusion (through a vein) once every three weeks to find the safest and most effective dose. Researchers will monitor your health closely to understand how your body responds to the treatment.
Current treatment options for these aggressive cancers have limited effectiveness, and many patients need new options. This medication targets a specific protein found on certain cancer cells, offering a potentially new way to fight these diseases.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an infusion through a vein once every three weeks. Between doses, you will have regular visits for blood tests, tumor assessments (imaging scans), and safety monitoring to check how you're responding and for any side effects. The study will track how your body processes the medication and whether your cancer shrinks or stays stable.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea